Lidak Gets Clearance For Antigen Technology

3 September 1995

Lidak Pharmaceuticals has received clearance from the US Food and Drug Administration to begin Phase I/II clinical trials of LP2307, a product based on Lidac's Large Multivalent Immunogen technology (isolated tumor antigens incorporated into microspheres), as a potential therapy for malignant melanoma.

Through its antigenic properties, LP2307 is intended to stimulate the patient's own immune system to combat indigenous tumor cells when administered as an injection. The investigation, which will run for approximately one year, will focus mainly on assessing the efficacy and safety of the drug in patients with late-stage III or IV of the cancer, for whom life expectancy is usually less than one year. An evaluation will be made of LP2307's ability to induce specific killer (cytotoxic) T lymphocyte reactions against melanoma cells and the possible prolongation of patient life with stabilization of the disease.

On the news of the FDA clearance, Lidak's stock rose 4.6% to $4.25. This follows the company being granted a notice of allowance for a US patent earlier this month (Marketletter August 14) on its Severe Combined ImmunoDeficiency (SCID) mouse model for the studying of immune system diseases, and similar notices for its free fatty acid assays.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight